PEGASTA 6ML INJ. PFS.

About

Pegasta 6ml Injection PFS (Pre-filled Syringe) contains Pegfilgrastim, a pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF). This medication is primarily used to stimulate the production of neutrophils, a type of white blood cell crucial for fighting infections. It works by binding to specific receptors on hematopoietic stem cells, promoting their proliferation, differentiation, and maturation into neutrophils, and enhancing their function.

Pegasta is most commonly administered to cancer patients undergoing myelosuppressive chemotherapy, which often leads to a significant drop in neutrophil counts (neutropenia). By increasing neutrophil levels, Pegasta helps to reduce the incidence and duration of febrile neutropenia, a serious complication that can lead to life-threatening infections and delays in chemotherapy cycles. Its pegylated formulation allows for a single dose per chemotherapy cycle, offering convenience and sustained action compared to daily G-CSF injections.

Uses

• Prevention of chemotherapy-induced neutropenia
• Reduction of the incidence of febrile neutropenia
• Used in patients with non-myeloid malignancies
• To allow for on-schedule delivery of chemotherapy

Directions For Use

Administer as a single subcutaneous injection once per chemotherapy cycle, at least 24 hours after chemotherapy. Do not administer within 14 days before the next chemotherapy dose.

Benefits

• Significantly reduces the risk of severe neutropenia
• Decreases the incidence of febrile neutropenia
• Helps maintain chemotherapy dose intensity and schedule
• Reduces the need for hospitalization due to infection
• Convenient single-dose administration per cycle
• Improves patient safety during chemotherapy treatment

Side Effects

• Bone pain
• Muscle pain (myalgia)
• Headache
• Fatigue
• Nausea
• Injection site reactions (redness, pain)
• Splenic rupture (rare but serious)
• Acute respiratory distress syndrome (ARDS) (rare)
• Allergic reactions
• Leukocytosis (excessive white blood cell count)
• Thrombocytopenia (low platelet count)
• Glomerulonephritis (kidney inflammation)

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but it's generally advisable to limit alcohol intake during chemotherapy treatment.
• Pregnancy - Use Pegasta during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult your doctor.
• Breastfeeding - It is unknown if Pegasta is excreted in human milk. A decision should be made whether to discontinue nursing or discontinue the drug.
• Liver - No specific dose adjustment is typically required for patients with liver impairment.
• Kidney - No specific dose adjustment is typically required for patients with renal impairment.
• Lung - Patients with pre-existing lung conditions, especially those with a history of ARDS, should be monitored closely for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.